Over the last 7 days, the market has dropped 1.6%, but it remains up by 15% over the past year, with earnings expected to grow by 16% annually. In such a climate, identifying stocks with solid financial health can be crucial for investors looking for growth opportunities. Penny stocks—often associated with smaller or newer companies—still hold potential when they demonstrate financial strength and long-term promise.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ATRenew (RERE)	$4.93	$1.14B	✅ 4 ⚠️ 0 View Analysis >
LexinFintech Holdings (LX)	$2.13	$380.28M	✅ 3 ⚠️ 2 View Analysis >
FinVolution Group (FINV)	$4.62	$1.2B	✅ 4 ⚠️ 1 View Analysis >
Tuniu (TOUR)	$0.7426	$89.35M	✅ 2 ⚠️ 3 View Analysis >
Information Services Group (III)	$3.11	$186.88M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.47	$362.72M	✅ 3 ⚠️ 1 View Analysis >
Cricut (CRCT)	$3.97	$857.71M	✅ 2 ⚠️ 2 View Analysis >
LifeVantage (LFVN)	$4.29	$54.93M	✅ 4 ⚠️ 3 View Analysis >
SIGA Technologies (SIGA)	$7.80	$357.51M	✅ 3 ⚠️ 1 View Analysis >

Click here to see the full list of 373 stocks from our US Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Grab Holdings (GRAB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Grab Holdings Limited operates the Grab superapp, offering various services across Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam with a market cap of approximately $15.29 billion.

Operations: The company's revenue is primarily derived from its Mobility segment at $1.22 billion, Deliveries at $1.80 billion, and Financial Services contributing $347 million.

Market Cap: $15.29B

Grab Holdings has demonstrated significant financial progress, achieving profitability with a net income of US$268 million for 2025, compared to a loss the previous year. The company’s revenue streams are robust, primarily from Mobility and Deliveries segments. Despite its improved earnings and cash exceeding total debt, concerns remain as operating cash flow covers only 5.8% of debt obligations. Recent strategic moves include a US$500 million share buyback program and an exclusive lidar distribution partnership with Hesai Technology in Southeast Asia, potentially enhancing its technological capabilities in autonomous systems. However, the board's average tenure is relatively short at 1.4 years.

• Click here to discover the nuances of Grab Holdings with our detailed analytical financial health report.
• Gain insights into Grab Holdings' outlook and expected performance with our report on the company's earnings estimates.

E.W. Scripps (SSP)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: The E.W. Scripps Company operates as a media enterprise with a portfolio of local television stations and national news and entertainment networks in the United States, with a market cap of approximately $323.59 million.

Operations: The company's revenue is primarily generated from its Local Media segment, which accounts for $1.35 billion, and its Scripps Networks segment, contributing $804.22 million.

Market Cap: $323.59M

E.W. Scripps faces challenges with its current unprofitability and a high net debt to equity ratio of 206%, indicating financial strain. Despite this, the company maintains a positive free cash flow, providing a cash runway exceeding three years. Recent earnings showed significant declines, with a net loss of US$28.5 million in Q4 2025 and US$100.88 million for the full year, reflecting operational difficulties. However, strategic initiatives like broadcasting the Professional Women's Hockey League's first-ever national game could enhance visibility and potentially drive future revenue growth as part of its commitment to expanding women's sports coverage.

• Dive into the specifics of E.W. Scripps here with our thorough balance sheet health report.
• Explore E.W. Scripps' analyst forecasts in our growth report.

Nuvation Bio (NUVB)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to developing cancer treatment product candidates, with a market cap of approximately $1.50 billion.

Operations: The company's revenue is primarily derived from its oncology development activities, totaling $62.90 million.

Market Cap: $1.5B

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, remains pre-revenue despite recent advances. The company reported a net loss of US$204.63 million for 2025, although revenue increased to US$62.90 million from the previous year. Nuvation's strategic collaboration with Eisai Co., Ltd. aims to broaden the reach of taletrectinib, a treatment for advanced ROS1-positive non-small cell lung cancer (NSCLC), with EMA validation recently secured for Europe and additional filings planned globally. Despite its unprofitability and high volatility, Nuvation holds substantial short-term assets exceeding liabilities and maintains an experienced management team.

• Click to explore a detailed breakdown of our findings in Nuvation Bio's financial health report.
• Gain insights into Nuvation Bio's future direction by reviewing our growth report.

Seize The Opportunity

• Click this link to deep-dive into the 373 companies within our US Penny Stocks screener.
• Looking For Alternative Opportunities? AI is about to change healthcare. These 126 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.